Rheumatoid Arthritis: research, articles & clinical reasoning tools
RheumaView Insights · New Series
The Female Endocrine Blind Spot in Rheumatology
Can female hormonal transitions change how treatment response is experienced, measured, and interpreted?This series takes up a question rarely addressed in rheumatoid arthritis research. It begins with the possibility that an apparent loss of biologic response does not always reflect renewed synovitis.
Menstrual cyclicity, pregnancy, the postpartum period, perimenopause, and menopause can influence pain, sleep, fatigue, body composition, medication exposure, and the composite scores used to define remission or treatment failure. Each of those variables sits inside the number a clinician reads at the visit.
Inflammatory assessment stays central. The narrower aim is to determine what has actually changed before an effective therapy is declared a failure.
Forthcoming in this series
- Cycle-related changes in disease classification
- Pregnancy and postpartum treatment interruption
- Pharmacokinetics and immunogenicity across reproductive states
- The reproductive variables largely absent from RA trials and registries
RheumaView™ Insights — research.rheumaview.com